Bionano Genomics (BNGO) Equity Average (2018 - 2026)

Bionano Genomics has disclosed Equity Average across 9 years of filings, most recently posting $40.9 million for Q1 2026.

• Equity Average for Q1 2026 came in at $40.9 million, down 2.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $40.9 million (down 2.01% YoY), and the FY2025 annual result was $39.9 million, down 39.33% from the prior year.
• Equity Average came in at $40.9 million for Q1 2026 at Bionano Genomics, down from $47.1 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $324.2 million in Q1 2022 to a low of $40.9 million in Q1 2026.
• The 5-year median for Equity Average is $89.5 million (2024), against an average of $141.8 million.
• Across the five-year window, Equity Average jumped 62.97% in 2022 and slumped 63.45% in 2024, its largest moves.
• Bionano Genomics' Equity Average stood at $265.6 million in 2022, then sank by 59.49% to $107.6 million in 2023, then plunged by 60.85% to $42.1 million in 2024, then increased by 11.85% to $47.1 million in 2025, then declined by 13.09% to $40.9 million in 2026.
• The last three Equity Average figures came in at $40.9 million (Q1 2026), $47.1 million (Q4 2025), and $47.6 million (Q3 2025), per Business Quant data.